DDInter1400 DDInter1676
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pazopanib {u} (Compound) treats {v} (Disease) kidney cancer
Pazopanib {u} (Compound) binds {v} (Gene) PIP4K2C
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
Pazopanib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C8 Inhibitors
Pazopanib {u} (Compound) downregulates {v} (Gene) MEST
Pazopanib {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Pazopanib (Compound) treats kidney cancer (Disease)
Pazopanib (Compound) binds PIP4K2C (Gene)
Pazopanib (Compound) upregulates SRC (Gene)
Pazopanib (Compound) is included by Cytochrome P450 2C8 Inhibitors (Pharmacologic Class)
Pazopanib (Compound) downregulates MEST (Gene)
Pazopanib (Compound) causes Rhinorrhoea (Side Effect)
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab